DEMONSTRATION OF PRECISE RELATIONSHIPS AND LINKS BETWEEN TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND PARKINSON’S DISEASE

Authors

  • Habib ur Rehman Department of Microbiology, University of Balochistan Quetta Pakistan
  • Kaleemullah Department of Microbiology, University of Balochistan Quetta Pakistan
  • Abdul Malik Tareen Department of Microbiology, University of Balochistan Quetta Pakistan

DOI:

https://doi.org/10.29121/granthaalayah.v7.i12.2019.320

Keywords:

Type 2 Diabetes Mellitus, Insulin Resistance, Parkinson:s Disease

Abstract [English]

Diabetes is a metabolic disorder that intessssrferes with the body's ability to consume food and convert it into energy. The most common mode of diabetes in type 2 diabetes mellitus (T2DM) is that the body cannot effectively use insulin produced by the pancreas. This is called insulin resistance. Parkinson's Disease (PD) is a chronic neurodegenerative motor defect whose properties work is hindrance with locomotion. This is due to the loss of neurons in the substantia nigra area under the brain that produces dopamine, a chemical messenger that transmits signals that produce smooth, meaningful movement. Dopamine loss caused by neuronal damage and death causes impaired movement. Cells rely on glucose for energy, and insulin helps to convert glucose into energy. In both Parkinson's disease and type 2 diabetes, changes in the brain can result in signaling interruptions that affect normal functioning. Insulin resistance also reaches the brain and produces severe changes in the nerve cells, increasing the risk of Parkinson's disease and abnormally promoting high blood sugar leads to high-rise the inflammation, associated with the development of Parkinson's disease. Diabetes suffering peoples are more likely to have Parkinson's disease. Parkinson's disease is 32% higher in people with type 2 diabetes than in non-diabetic patients. Patients with type 2 diabetes along with its complication have a 49% higher risk of Parkinson’s disease, while those having only type 2 diabetes without complications have a 30% risk of parkinson’s disease. In particular, younger patients with diabetes (25 to 44 years of age) have an approximately fourfold increased risk of developing Parkinson's compared with adults of similar age without diabetes. Researchers has estimated the high risk of developing PD based on longitudinal data methodology for people with type 2 diabetes. Initial studies have reported more than 400 genes linked in both conditions. The potential link between type 2 diabetes and Parkinson's disease has been the topic of medical dialogue and scientific research for years. Recently, animal and in vitro studies have shown that the pathophysiology and clinical symptoms of Parkinson's disease are concerned more with insulin dysregulation and changes in insulin action.

Downloads

Download data is not yet available.

References

Aviles-Olmos, I., Patricia, L., Andrew, L. and Thomas, F. (2013). Parkinson’s disease, insulin resistance and novel agents of neuroprotection. Brain A Journal of Neurology, 136: 374–384.

Ashraghi, M. R., Pagano, G., Polychronis, S., Niccolini, F. and Politis, M. (2016). Parkinson’s disease, diabetes, impairment cognitive. Recent Pat Endocr Metab Immune Drug Discov,10:11-21.

Athauda, D., Maclagan, K. and Skene, S. S. (2017). Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet, 390: 1664–1675.

Barbeau, A., Giguere, R. and Hardy, J. (1961). Clinical experience with tolbutamide in Parkinson’s disease. Union Med Can, 90: 147–51.

Belsham, D. D., Fick, L. J., Dalvi, P. S., Centeno, M. L., Chalmers, J. A. and Lee, P. K. (2009). Ciliary neurotrophic factor recruitment of glucagon-like peptide-1mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB, J, 23: 4256–65.

Bohnen, N. I., Kotagal, V. and Muller. M. L. (2014). Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord, 20:1394–1398.

Boyd, A. E., Lebovitz, H.E. and Feldman, J. M. (1971). Endocrine function and glucose metabolism in patients with Parkinson’s disease and their alternation by L-Dopa. J Clin Endocrinol Metab, 33: 829–37.

Boulton, A. J., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L. and Freeman, R. (2005). Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care, 28: 956–62.

Chalmanov, V. and Vurbanova, M. (1987). Diabetes mellitus in parkinsonism patients. Vutr Boles, 26: 68–73.

Craft, S. and Watson, G.S. (2004). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol, 3:169–78.

Elner, A. M. and Kandel, E.I. (1965). Studies on the Carbohydrate metabolism in Parkinsonism. (Relation of Carbohydrate metabolism disorders to the clinical picture of the disease). Zh Nevropatol Psikhiatr Im S S Korsakova, 65: 46–50.

Fan, R., Li, X., Gu, X., Chan, J. C. and Xu, G. (2010). Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab, 12: 815–24.

Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E, Biggs, C. S. and Whitton, P.S. (2008). Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuro-inflammation, 5: 19.

Huang, H. C., Tsai, C. H. and Muo, C. H. (2015). Risk of Parkinson’s disease following zolpidem use: a retrospective, population-based cohort study. J Clin Psychiatry, 76: 104–10.

Hu, G., Jousilahti, P., Bidel, S., Antikainen, R. and Tuomilehto, J. (2007). Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care, 30: 842-7.

International Diabetes Federation. (2015). IDF Diabetes Atlas Seventh Edition.

International Diabetes Federation and World Health Organization. (2015). The diabetes declaration and strategy; a call to action and plan of action to prevent and control diabetes and related chronic diseases.

Jin, H., Kanthasamy, A. and Ghosh, A, (2014). Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochim Biophys Acta, 1842:1282-94.

Kaplan, E. L. and Meier, P. (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53:457-81.

Kim, S., Moon, M. and Park, S. (2009). Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol, 202: 431-9.

Kwak, S. H., Park, K.S. and Lee, K. U. (2010). Mitochondrial metabolism and diabetes. J Diabetes Investig,1:161-9.

Lipman, I. J., Boykin, M. E. and Flora, R. E. (1974). Glucose intolerance in Parkinson’s disease. J Chronic Dis, 27: 573-9.

Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W. and Greig, N. H. (2010). Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem, 113: 1621–31.

Liao, P. J., Lin, Z. Y. and Huang, J. C. (2015). The relationship between type 2 diabetic patients’ early medical care-seeking consistency to the same clinician and health care system and their clinical outcomes. Medicine, 94: 554.

Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E. and O’Brien, P. C.(1997). Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol, 145: 301-308.

Lu, L., Fu, D. L. and Li, H. Q. (2014). Diabetes and risk of Parkinson’s disease: an updated meta-analysis of case-control studies. PLoS ONE, 9: 85781.

Manish, K. G., Pardeep, K., and Jugal K. (2010). Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res, 1(4): 274-278. doi: 10.4103/0974-7788.76794. DOI: https://doi.org/10.4103/0974-7788.76794

Morris, J. K., Vidoni, E. D. and Perea, R,D (2014). Insulin resistance and gray matter volume in neurodegenerative disease. Neuroscience, 270:139-47.

Michell, A. W., Xu, Z., Fritz, D., Lewis, S. J. and Foltynie, T.(2006). Saccadic latency distributions in Parkinson's disease and the effects of Ledopa. Exp Brain Res, March 17. DOI: https://doi.org/10.1007/s00221-006-0412-z

Noyce, Alastair, Lees, and Andrew (2017). Observations on a 2-Step Approach to Screening for Parkinson Disease. JAMA Neurology/jamaneurol, 3202. DOI: https://doi.org/10.1001/jamaneurol.2017.3202

Okun, M. S., Jacob, M. D., Jones, D., Paul-Mangal, M.S., Jacob-Lafo, M.S. and Dawn-Bowers., M.S. (2016). Mood Differences Among Parkinson’s Disease Patients With Mild Cognitive Impairment Ph.D.Published Online:21, https://doi.org/10.1176/appi.neuropsych.15090221. DOI: https://doi.org/10.1176/appi.neuropsych.15090221

Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A., Hofman, A., Breteler, M. M. (1999). Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 53: 1937-42.

Peila, R., Rodriguez, B. L. and Launer, L. J. (2002). Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes, 51: 1256-62.

Politis, Marios & Reza Ashraghi, Mohammad & Pagano, Gennaro & Polychronis, Sotirios & Niccolini, and Flavia (2016). Parkinson's Disease, Diabetes and Cognitive Impairment. Recent patents on endocrine, metabolic & immune drug discovery. 10. 10.2174/1872160630191119. DOI: https://doi.org/10.2174/1872214810666160630191119

Pressley, J. C., Louis, E. D., Tang, M. X., Cote, L., Cohen, P. D. and Glied, S. (2003). The impact of comorbid disease and injuries on resource use and expenditures in Parkinsonism. Neurology, 60: 87-93.

Saguil, A. and Lax, J. W. (2014). Acute migraine treatment in emergency settings. Am Fam Physician, 89:742-4.

Santiago, J. A. and Potashkin, J. A. (2013). Shared dysregulated pathways lead to Parkinson’s disease and diabetes. Trends Mol Med,19:176–86.

Sandy, k. R. (1993). The relationship between diabetes mellitus and Parkinson’s disease. Int J Neurosci, 69: 125-30.

Schapira, A. H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol, 7: 97-109.

Schwab, R. S. (1960). Progression and prognosis in Parkinson’s disease. J Nerv Ment Dis, 130: 556–66.

Schapira, A. H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol, 7:97-109.

Sun, Y., Chang, Y. H. and Chen, H. F.(2012). Risk of Parkinson disease onset in patients with diabetes: A 9-year population-based cohort study with age and sex stratifications. Diabetes Care, 35:1047-9.

Szendroedi, J., Phielix, E. and Roden, M. (2012) The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol, 8:92-103. DOI: https://doi.org/10.1038/nrendo.2011.138

Tuomilehto, J., Rastenyte, D., Jousilahti, P., Sarti, C. and Vartiainen, E. (1996). Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke, 27: 210-5.

Van-Woert, M. H. and Mueller, P. S. (1971). Glucose, insulin, and free fatty acid metabolism in Parkinson’s disease treated with levodopa. Clin Pharmacol Ther, 12: 360-7.

Warner, T.T., Casper, C. J., Taanman, J. W. and Nathwani, A.C. (2012). Generation of iPS-derived dopaminergic neurons as an in-vitro model of rapid-onset dystonia parkinsonism. Hum Gene Therapy, 22, A42-A43.

Wahlqvist, M. L., Lee, M. S. and Hsu, C.C. (2012). Metformin-inclusive sulfonylureatherapy reduces the risk of Parkinson’s disease occurring with type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord,18:753-8.

Wiederkehr, A. and Wollheim, C. B. (2006). Minireview: implication of mitochondria in insulin secretion and action. Endocrinology, 147:2643-9.

Yue, X., Li, H., Yan, H., Zhang, P., Chang, L. and Li, T. (2016). Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine, 95: 3549.

Yu-Wan, Y., Teng-Fu, H., Chia-Ing, L., Chiu-Shong, L., Wen-Yuan, L. and Jen-Huai, C. (2008). Increased risk of Parkinson disease with diabetes mellitus in a population-based study Journal of Medicine, 96: 1-10.

Zimmet, P., Alberti, K. G., Shaw, J. (2001). Global and societal implications of the diabetes epidemic. Nature, 414: 782-7 DOI: https://doi.org/10.1038/414782a

Downloads

Published

2020-06-09

How to Cite

Rehman, H. ur, Kaleemullah, & Tareen, A. M. (2020). DEMONSTRATION OF PRECISE RELATIONSHIPS AND LINKS BETWEEN TYPE 2 DIABETES MELLITUS, INSULIN RESISTANCE AND PARKINSON’S DISEASE. International Journal of Research -GRANTHAALAYAH, 7(12), 259–270. https://doi.org/10.29121/granthaalayah.v7.i12.2019.320